Extended panel of biomarkers for long term monitoring of effectiveness of 3 direct antiviral regimen in HCV genotype 1b infection: results from a Romanian infectious disease hospital
By:
References
- 1. Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis 2008;12:661–74. DOI: 10.1016/j.cld.2008.03.00710.1016/j.cld.2008.03.00718625433
- 2. Stanciu C, Trifan A. Hepatitis C Virus Treatment Revolution: Eastern European Story Hepat Mon 2015;15(7):e28969. DOI: 10.5812/hepatmon.28969v210.5812/hepatmon.28969v2453973126300932
- 3. Hilgenfeldt EG, Schlachterman A, Firpi RJ. Hepatitis C: Treatment of difficult to treat patients. World J Hepatol 2015;7(15):1953–63. DOI: 10.4254/wjh.v7.i15.195310.4254/wjh.v7.i15.1953451715426244069
- 4. Pimpin L, Cortez-Pinto H, Negro F, Corbould E, Lazarus JV, Webber L et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol 2018;69(3):718–35. DOI: 10.1016/j.jhep.2018.05.01110.1016/j.jhep.2018.05.01129777749
- 5. Viekirax® (AbbVie). Rezumatul caracteriticilor produsului [online]. [2015] [cited 2019 December 9]; Available from: URL: https://www.ema.europa.eu/en/documents/product-information/viekirax-epar-product-information_ro.pdf
- 6. Exviera® (AbbVie). Rezumatul caracteriticilor produsului [online]. [2015] [cited 2019 December 9]; Available from: URL: https://www.ema.europa.eu/en/documents/product-information/exviera-epar-product-information_ro.pdf
- 7. Protocol terapeutic corespunzator DCI Ombitasvirum + Paritaprevirum + Ritonavirum + DCI Dasabuvirum [online]. [2015] [cited 2019 December 9]; Available from: URL: http://www.cnas.ro/page/tratament-fara-interferon-3.html
- 8. Streinu-Cercel A. Hepatitis C burden in Romania 2016–2017 Evaluation 2018 challenges [online]. [cited 2019 December 9]; Available from: URL: http://www.vhpb.org/files/html/Meetings_and_publications/Presentations/BUCH32.pdf
- 9. Covic A, Iancu LS, Apetrei C, Scripcaru D, Volovat C, Mititiuc LI et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999;14:40–5. DOI: 10.1093/ndt/14.1.4010.1093/ndt/14.1.4010052474
- 10. Gheorghe L, Iacob S, Csiki IE. Prevalence of hepatitis C in Romania. Different from European rates. J Hepatol 2008;49:658–63. DOI: 10.1016/j.jhep.2008.06.01610.1016/j.jhep.2008.06.01618684541
- 11. Voiculescu M, Iliescu L, Ionescu C, Micu L, Ismail G, Zilisteanu D et al. A Cross-Sectional Epidemiological Study of HBV, HCV, HDV and HEV Prevalence in the SubCarpathian and South-Eastern Regions of Romania. J Gastrointestin Liver Dis 2010; 19(1):43–8.
- 12. European Centre for Disease Prevention and Control. Hepatitis C. In: ECDC. Annual epidemiological report for 2016 [online]. [2018] [cited 2019 December 9]; Available from: URL: https://www.ecdc.europa.eu/en/publications-data/hepatitis-c-annual-epidemiological-report-2016
- 13. Popovici O, Molnar GB, Popovici F, Janţă D, Pistol A, Azoicăi D. A Seroprevalence Study of Hepatitis B and C Virus Infections in a Hospitalized Population in Romania, an Opportunity for a Better National Prevention and Control Strategy. J Gastrointestin Liver Dis 2016;25(1):25–32. DOI: 10.15403/jgld.2014.1121.251. hbc10.15403/jgld.2014.1121.251
- 14. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31(2):30–60. DOI: 10.1111/j.1478-3231.2011.02539.x10.1111/j.1478-3231.2011.02539.x21651702
- 15. Ahmed H, Abushouk AI, Menshawy A, Mohamed A, Negida A, Loutfy SA et al. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis. Clin Drug Investig 2017;37(11):1009–23. DOI: 10.1007/s40261-017-0565-510.1007/s40261-017-0565-528871475
- 16. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973–82. DOI: 10.1056/NEJMoa140286910.1056/NEJMoa140286924725237
- 17. Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C et al. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine 2017;96(50):e9271. DOI: 10.1097/MD.000000000000927110.1097/MD.0000000000009271
- 18. Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A et al. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol 2017;2:427–34. DOI: 10.1016/S2468-1253(17)30048-110.1016/S2468-1253(17)30048-1
- 19. Danilau D, Malich N, Litvinchuk D, Karpov I. Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus. Clin Exp Hepatol 2017;3(3):164–68. DOI: 10.5114/ceh.2017.7028110.5114/ceh.2017.70281
- 20. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New England J Med 2014;370:1604–14. DOI: 10.1056/NEJMoa140156110.1056/NEJMoa1401561
- 21. Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. Clin Infect Dis 2015;60:608−10. DOI: 10.1093/cid/ciu86510.1093/cid/ciu865
- 22. Calleja JL, Rincon D, Ruiz-Antoran B, Sacristan B, Perello C, Lens S et al. Effectiveness and safety of ombitasvir and paritaprevir, ritonavir and dasabuvir patients with genotype 1 chronic hepatitis C virus infection: results from Spanish real world cohort. J Hepatol 2016; 64(2):218–19. DOI: 10.1016/S0168-8278(16)00189-610.1016/S0168-8278(16)00189-6
- 23. Agarwal K, Gaeta GB, Lee SS, Dumas EO, A Streinu-Cercel, E Schote et al. Long-term clinical outcomes in HCV genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: First interim safety and efficacy results from TOPAZ-I [online]. [2016] [cited 2019 December 9]; Available from: URL: http://www.natap.org/2016/AASLD/AASLD_54.htm
- 24. Preda CM, Popescu CP, Baicus C, Voiosu TA, Manuc M, Pop CS et al. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis. Liver Int 2018;38(4):602–10. DOI: 10.1111/liv.1355010.1111/liv.1355028816020
- 25. Dinu S, Țârdei G, Ceauşu E, Florescu SA, Micu L, Ecobici AM et al. Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania. Rev Romana Med Lab. 2018;26(4):443–9. DOI: 10.2478/rrlm-2018-002910.2478/rrlm-2018-0029
Language: English
Page range: 93 - 103
Submitted on: Sep 14, 2020
Accepted on: Nov 15, 2020
Published on: Jan 29, 2021
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2021 Ioana-Alina Harja-Alexa, Luca Catalina Mihaela, Carmen Doina Manciuc, Andrei Vata, Aida Badescu, Mihnea-Eudoxiu Hurmuzache, Alexandra Mirela Ciocan, Ioana Maria Hunea, Luminita-Smaranda Iancu, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.